QNRX 0.85 Quoin Pharmaceuticals, Ltd.
| Range: | 0.477-6.18 | Vol Avg: | 1850839 | Last Div: | 0 | Changes: | 0.19 |
| Beta: | 2.03 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Aug 01 2016 | Empoloyees: | 4 | ||
| CUSIP: | 74907L102 | CIK: | 0001671502 | ISIN: | US74907L3006 | Country: | US |
| CEO: | Dr. Michael Myers Ph.D. | Website: | https://quoinpharma.com | ||||
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow